NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sarepta Therapeutics, Inc. securities between June 22, 2023, and June 24, 2025, of the upcoming lead plaintiff deadline on August 25, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Sarepta made false and misleading statements regarding its gene therapy product, ELEVIDYS, which posed significant safety risks and failed to detect severe side effects during trials [5]. - The adverse events related to ELEVIDYS treatment led to a halt in recruitment and dosing in trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [5].

Core Insights - Crown Holdings, Inc. has been recognized by Forbes as the top packaging company on track to achieve net-zero carbon emissions, ranking 22nd overall among 200 evaluated companies [1][2] Group 1: Recognition and Achievements - Crown's recognition as a Net Zero Leader for 2025 highlights the dedication of its global team towards sustainability goals [2] - The company ranked 22nd in emissions projections, risk management, financial strength, governance, and organizational preparedness [1] Group 2: Sustainability Initiatives - Crown's Twentyby30™ initiative, established in 2020, serves as a roadmap for achieving its net zero target, focusing on emissions reductions, water preservation, recycling, and ethical sourcing [3] - The company emphasizes that sustainability is central to its business, fostering innovation and progress in reducing its carbon footprint [4] Group 3: Reporting and Transparency - Crown's 2024 Sustainability Report titled "Built to Last" provides measurable data on its sustainability progress and highlights environmental and social goals that have been achieved or surpassed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The class action lawsuit has been filed against PepGen Inc. for misleading statements regarding the effectiveness and safety of its drug PGN-EDO51 and the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4]. - The deadline to move the Court to serve as lead plaintiff is August 8, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overall commercial prospects of the drug [4]. - The misleading public statements led to investor damages when the true information became known [4].

Core Points - Rosen Law Firm is reminding investors who purchased 3D Systems Corporation securities between August 13, 2024, and May 12, 2025, of the lead plaintiff deadline on August 12, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that during the Class Period, 3D Systems made false and misleading statements regarding its business performance and the impact of weakened customer spending [4] - The updated milestone criteria in a partnership with United Therapeutics Corporation is claimed to negatively affect 3D Systems' Regenerative Medicine Program revenue [4] - The lawsuit asserts that the public statements made by 3D Systems were materially false and misleading, leading to investor damages when the true information was revealed [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [3] - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [3]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of iRobot Corporation securities purchasers during the specified Class Period, indicating potential legal issues for the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between January 29, 2024, and March 11, 2025, and aims to address misleading statements made by iRobot regarding its financial stability and restructuring plans [1][5]. - The lawsuit claims that iRobot overstated the effectiveness of its Restructuring Plan following the termination of the Amazon Acquisition, leading to doubts about its ability to operate profitably as a standalone entity [5]. Group 2: Investor Information - Investors who purchased iRobot securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Apple Inc. for allegedly making false and misleading statements regarding the integration of advanced AI-based features into its devices, which may have impacted investor decisions and the company's financial prospects [4]. Group 1: Class Action Details - The class period for the lawsuit is from June 10, 2024, to June 9, 2025, and the lead plaintiff deadline is August 19, 2025 [1]. - Investors who purchased Apple securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - A lead plaintiff acts on behalf of other class members in directing the litigation and must file a motion with the court by the specified deadline [2]. Group 2: Allegations Against Apple - The lawsuit claims that Apple misstated the timeline for integrating advanced AI-based Siri features, making it unlikely these features would be available for the iPhone 16 [4]. - The absence of these advanced features is alleged to negatively impact iPhone 16 sales, leading to overstated business and financial prospects for Apple [4]. - The lawsuit asserts that Apple's public statements were materially false and misleading throughout the class period, resulting in investor damages when the truth was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [5]. - When the true details became public, investors reportedly suffered damages due to the misleading information [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that DoubleVerify's high-margin advertising optimization services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5]. - The lawsuit also states that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and that its risk disclosures were materially misleading [5].

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of 3D Systems Corporation (NYSE: DDD) between August 13, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important August 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased 3D Systems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...